| Laboratory: | Clinical Biochemistry | ||||
| Test Name: |
CA125 - (P)
Test Code:
CA12
|
||||
| Clinical Information: |
Alternate Name: Cancer Antigen 125
Test Indications: This test is used to monitor ovarian cancer treatment and to detect recurrence. It should not be used for cancer screening in the general population. Patient Preparation Instructions: Multivitamins (45–125 µg biotin) or biotin-only supplements up to 1 mg per day do not interfere with this test. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. >5 mg/day) until at least 8 hours after the last dose. Additional Information: The test method used is an Electrochemiluminescence (ECLIA) assay manufactured by Roche Diagnostics Inc. and performed on the Cobas Elecsys system. Patient results determined by different assay manufacturers or methods are not comparable and cannot be used interchangeably for patient monitoring. |
||||
| Collection Devices: |
|
||||
| Specimen Required: |
Plasma: 2.0 mL
Pediatric Plasma: 0.25 mL
Stability 5 days refrigerated, 24 weeks frozen |
||||
| Referral: |
Serum: 2.0 mL
Samples must be transferred to an aliquot tube and stored frozen if analysis will not be complete within 48 hours (#110-10-05 Serum / Plasma Separation Procedure & Transport)
|
||||
| Requisition: | |||||
| Reference Values: |
0 - 34 U/mL
|
||||
| Availability: |
Daily
|
||||
| See Also: | |||||
| More Information: |